On July 14, 2017, BGI Genomics was officially listed and became the 2001st listed company of the Shenzhen Stock Exchange. BGI Genomics is one of the world's leading genomics test and research service providers, providing genomics test and research services for medical institutions, research institutions, enterprises and institutions through genetic testing and other means. BGI Genomics is committed to helping and accelerating scientific innovation, strengthening the prevention and control of cancer and other genetic diseases, improving diagnostic tools for the rapid diagnosis of infectious disease and helping the development of precision medicine. Relying on cutting edge bioinformatics pipelines, advanced R&D, high-performance proprietary NGS sequencing technology, mass spectrometers,and underpinned by a decade of commercial experience, BGI Genomics provides its customers with expert and affordable clinical molecular diagnostic solutions and NGS services for research.